NCT03354455

Brief Summary

Using a within-subject cross-over design, we will include 20 patients with Parkinson disease (PD) and peak-of-dose dyskinesia. Patients will be studied after withdrawal from their normal dopaminergic medication. On two separate days, each patient will receive off-line, effective (high-intensity) or ineffective (low-intensity) 1 Hz repetitive transcranial magnetic stimulation (rTMS) of the presupplementary motor area (preSMA) before functional magnetic resonance (fMRI). Immediately after the patient will perform a Go/No-Go task during fMRI in the the OFF state for 9 minutes. Then the scan is paused and the patient will receive 200 mg fast-acting oral levodopa and undergo whole-brain task-related fMRI at 3 Tesla until peak-of-dose dyskinesia will emerge. During task-related fMRI, patients has to click on a mouse with their right hand (Right-Go), left hand (Left-Go), or no action (No-Go) in response to arbitrary visual cues. The patients will also be tested for different aspects of impulsivity using neuropsychological questionnaires and computerized tests.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 1, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

August 1, 2017

Completed
4 months until next milestone

First Posted

Study publicly available on registry

November 28, 2017

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 16, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 16, 2018

Completed
Last Updated

August 6, 2019

Status Verified

August 1, 2018

Enrollment Period

1.1 years

First QC Date

June 1, 2017

Last Update Submit

August 3, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Levodopa-induced change in task-related regional neural activity as indexed by the blood oxygen level dependent (BOLD) signal

    A single priming session of REAL rTMS over the preSMA will attenuate the abnormal pharmacodynamic BOLD response (which is an index of regional neural activity) in the cortico-basal ganglia loop after levodopa challenge compared with SHAM rTMS.

    Within the first 60 minutes after levodopa intake

Secondary Outcomes (2)

  • Onset of LID

    Within the first 60 minutes after levodopa intake

  • Severity of LID

    Within the first 60 minutes after levodopa intake

Study Arms (2)

REAL TMS

EXPERIMENTAL

30 minutes of repetitive transcranial magnetic stimulation with 100% of the patients' individual resting motor threshold.

Device: Repetitive transcranial magnetic stimulation

SHAM TMS

SHAM COMPARATOR

30 minutes of repetitive transcranial magnetic stimulation with 30% of the patients' individual resting motor threshold.

Device: Repetitive transcranial magnetic stimulation

Interventions

Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses). Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot.

REAL TMSSHAM TMS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of Parkinson's Disease (Hoehn \& Yahr 1-3)
  • Peak-of-dose levodopa-induced dyskinesia

You may not qualify if:

  • Insufficient Danish language skills
  • Neurological disease other than Parkinson's Disease
  • Major psychiatric illness
  • Sedatives or serotonergic medication in their current treatment.
  • Severe tremor
  • Montreal Cognitive Assessment score \< 26
  • Contraindication for transcranial magnetic stimulation:
  • Epilepsy or epilepsy in 1st degree relatives
  • Contraindications for MRI-scanning:
  • Pacemaker
  • Pregnancy
  • Metallic foreign objects inside the body
  • Severe claustrophobia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Danish Research Centre for Magnetic Resonance

Hvidovre, Capital Region, 2650, Denmark

Location

MeSH Terms

Conditions

Dyskinesia, Drug-InducedParkinson Disease

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

DyskinesiasMovement DisordersCentral Nervous System DiseasesNervous System DiseasesNeurologic ManifestationsNeurotoxicity SyndromesSigns and SymptomsPathological Conditions, Signs and SymptomsDrug-Related Side Effects and Adverse ReactionsChemically-Induced DisordersPoisoningParkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesSynucleinopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Officials

  • Hartwig R Siebner, MD, DMSci

    Danish Research Centre for Magnetic Resonance

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Sham stimulation
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2017

First Posted

November 28, 2017

Study Start

August 1, 2017

Primary Completion

September 16, 2018

Study Completion

September 16, 2018

Last Updated

August 6, 2019

Record last verified: 2018-08

Locations